Physician profile
Peter Michael Hunkus
NPI 1780297945
$2,916.40
in general payments reported to CMS, 2019-2025
33 companies · $19.76 in 2025
The $19.76 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $426 · 2022: $708 · 2023: $1,131 · 2024: $631 · 2025: $19.76.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,782.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,781.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $889.64 | 2021-2024 | |
| Novo Nordisk INC | $266.31 | 2021-2024 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $254.32 | 2021-2024 | Airsupra, Breztri, Farxiga |
| Pfizer INC. | $171.89 | 2021-2024 | |
| Glaxosmithkline, LLC. | $169.60 | 2022-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $152.43 | 2021-2023 | Trulance, Xifaxan |
| Lilly USA, LLC | $145.55 | 2022-2024 | Jardiance, Mounjaro, Zepbound |
| Janssen Pharmaceuticals, INC | $126.20 | 2022-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $121.35 | 2022-2024 | Jardiance, Ofev |
| Novartis Pharmaceuticals Corporation | $73.85 | 2021-2023 | |
| Collegium Pharmaceutical, INC. | $52.65 | 2021 | |
| Xeris Pharmaceuticals, INC. | $51.98 | 2022-2023 | Gvoke Hypopen |
| E.R. Squibb & Sons, L.L.C. | $36.98 | 2022-2024 | Camzyos |
| Exact Sciences Corporation | $35.38 | 2023-2024 | Cologuard Collection Kit |
| Amarin Pharma, INC. | $34.80 | 2021 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $29.15 | 2024 | Veozah |
| Biohaven Pharmaceutical Holding Company LTD. | $27.93 | 2022 | |
| Amgen INC. | $23.59 | 2021 | |
| Sumitomo Pharma America, INC. | $19.92 | 2024 | Gemtesa |
| Phathom Pharmaceuticals, INC. | $19.76 | 2025 | Voquezna |
| Otsuka America Pharmaceutical, INC. | $19.05 | 2024 | Rexulti |
| Ultragenyx Pharmaceutical INC. | $18.88 | 2022 | |
| Inspire Medical Systems, INC. | $17.69 | 2024 | Inspire |
| Idorsia Pharmaceuticals US INC | $17.63 | 2023 | Quviviq |
| Lundbeck LLC | $17.39 | 2024 | Rexulti |
| Grt US Holding, INC. | $17.18 | 2021 | |
| Merck Sharp & Dohme LLC | $17.11 | 2021 | |
| Nestle Healthcare Nutrition INC. | $17.00 | 2022 | |
| Qiagen, LLC | $15.76 | 2024 | |
| Biohaven Pharmaceuticals, INC. | $15.06 | 2021 | |
| Horizon Therapeutics Plc | $14.68 | 2022 | |
| Almatica Pharma LLC | $13.81 | 2021 | |
| Redhill Biopharma INC. | $11.88 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Hunkus listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.